Recombinant monoclonal antibody to HER2/neu. This antibody intended for the prophylaxis and treatment of HER2-positive breast cancer.
Figure 1 HuA21 suppressed the proliferation of breast cancer cells.
The inhibitory effects of HuA21, trastuzumab (Tra), or the combination on the growth of the: BT-474 (A); BT-474/HR (B); and SKBR3 (C) cells. The cells were incubated with HuA21 or Tra at the indicated concentrations for 72 h. Cell viability was measured by the the cell counting kit-8 (CCK-8) assay. The curve charts represent the cell viability of the: BT-474 (A); BT-474/HR (B); and SKBR3 cells (C). The experiments are performed in triplicate, and the data are representative of three separate experiments. # p < 0.05 vs. control; & p < 0.05 vs. HuA21-treated cells.
Li, R., Hu, S., Chang, Y., Zhang, Z., Zha, Z., Huang, H., ... & Wei, W. (2016). Development and characterization of a humanized anti-HER2 antibody HuA21 with potent anti-tumor properties in breast cancer cells. International journal of molecular sciences, 17(4), 563.
Figure 2 HuA21-mediated ADCC against HER2-positive breast cancer cells.
HuA21-mediated ADCC against HER2-positive breast cancer cells BT-474 cells were pre-incubated with the indicated concentrations of HuA21 or trastuzumab (Tra). The ADCC experiments were performed in triplicate, and the data are representative of three separate experiments.
Li, R., Hu, S., Chang, Y., Zhang, Z., Zha, Z., Huang, H., ... & Wei, W. (2016). Development and characterization of a humanized anti-HER2 antibody HuA21 with potent anti-tumor properties in breast cancer cells. International journal of molecular sciences, 17(4), 563.
Figure 3 HuA21 suppressed the migration of breast cancer cells.
The representative images and bar graph indicate the inhibitory effects of HuA21 (10 µg/mL), trastuzumab (Tra, 10 µg/mL), or HuA21 (10 µg/mL) + Tra (10 µg/mL) on the migration of SKBR3 breast cancer cells. The cells were treated with HuA21, Tra, or HuA21 + Tra for 24 h. Magnification: 100×. * p < 0.05 vs. control; & p < 0.05 vs. HuA21-treated cells. The experiments were performed in triplicate, and the data are representative of three separate experiments.
Li, R., Hu, S., Chang, Y., Zhang, Z., Zha, Z., Huang, H., ... & Wei, W. (2016). Development and characterization of a humanized anti-HER2 antibody HuA21 with potent anti-tumor properties in breast cancer cells. International journal of molecular sciences, 17(4), 563.
Figure 4 HuA21 inhibited HER2 receptor-related signaling pathways.
Western blot and the representative picture showing the bands of EGFR, p-HER2, total HER2, total HER3, p-Akt, total Akt, p-Erk1/2, and total Erk1/2 expressed in the BT-474 treated with HuA21, trastuzumab (Tra), or HuA21 + Tra. β-Actin was used as the loading control. * p < 0.05 vs. control; & p < 0.05 vs. HuA21-treated cells. The experiments were performed in triplicate, and the data are representative of three separate experiments.
Li, R., Hu, S., Chang, Y., Zhang, Z., Zha, Z., Huang, H., ... & Wei, W. (2016). Development and characterization of a humanized anti-HER2 antibody HuA21 with potent anti-tumor properties in breast cancer cells. International journal of molecular sciences, 17(4), 563.
Figure 5 HuA21 enabled internalization in HER2-positive cancer cells.
The BT-474cells were incubated with FITC-conjugated HuA21 or FITC-conjugated trastuzumab (Tra) for the indicated time periods, and then the presence of HuA21 or Tra was revealed by fluorescence microscope. Representative photomicrographs showing HuA21 or Tra (Green: FITC-conjugated HuA21 or Tra, scale bar = 50 µm).
Li, R., Hu, S., Chang, Y., Zhang, Z., Zha, Z., Huang, H., ... & Wei, W. (2016). Development and characterization of a humanized anti-HER2 antibody HuA21 with potent anti-tumor properties in breast cancer cells. International journal of molecular sciences, 17(4), 563.
Figure 6 HuA21 enabled internalization in HER2-positive cancer cells.
The BT-474 cells were incubated with HuA21 or Tra for 4 h, FITC-conjugated secondary antibody was added and the signal was detected by confocal microscopy (Green: FITC-conjugated HuA21 or Tra; nuclei (blue) was stained by 4',6-diamidino-2-phenylindole (DAPI), scale bar = 50 µm)
Li, R., Hu, S., Chang, Y., Zhang, Z., Zha, Z., Huang, H., ... & Wei, W. (2016). Development and characterization of a humanized anti-HER2 antibody HuA21 with potent anti-tumor properties in breast cancer cells. International journal of molecular sciences, 17(4), 563.
Figure 7 HuA21 enabled internalization in HER2-positive cancer cells.
The BT-474cells were incubated with Tra or HuA21 for the indicated periods. HuA21 or Tra on the cellsurface was labeled with a FITC-conjugated secondary antibody and analyzed by flow cytometry.
Li, R., Hu, S., Chang, Y., Zhang, Z., Zha, Z., Huang, H., ... & Wei, W. (2016). Development and characterization of a humanized anti-HER2 antibody HuA21 with potent anti-tumor properties in breast cancer cells. International journal of molecular sciences, 17(4), 563.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
NABG-059 | Recombinant Anti-Human ERBB2 VHH Single Domain Antibody | IHC, FC, CA, FuncS | Llama VHH |
HPAB-0201-FY | Recombinant llama Anti-ERBB2 Antibody (VHH6) | E | llama VHH |
HPAB-0202-FY | Recombinant llama Anti-ERBB2 Antibody (VHH1) | E | llama VHH |
HPAB-0203-FY | Recombinant llama Anti-ERBB2 Antibody | IF | llama VHH |
HPAB-0725-YJ-VHH | Camelid Anti-ERBB2 Recombinant Single Domain Antibody (SR-87) | ELISA | Camelid VHH |
CAT | Product Name | Application | Type |
---|---|---|---|
IAB-B008(A) | Recombinant Anti-human ERBB2 Intrabody [(D-Arg)9] | IF, FC, FuncS | scFv-(D-Arg)9 |
IAB-B008(G) | Recombinant Anti-human ERBB2 Intrabody [+36 GFP] | WB, ICC, FuncS | scFv-(+36GFP) |
IAB-B008(T) | Recombinant Anti-human ERBB2 Intrabody [Tat] | ICC, Neut, FuncS | scFv-Tat |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-005 | Anti-Human ErbB2 Recombinant Antibody (Trastuzumab) | FC, IP, ELISA, Neut, FuncS, IF, IHC | IgG1 - kappa |
TAB-033CT | Human Anti-ERBB2 Recombinant Antibody (TAB-033CT) | ELISA, WB | Human IgG1, κ |
TAB-038CT | Human Anti-ERBB2 Recombinant Antibody (TAB-038CT) | FuncS, FC | Humanized IgG1 |
TAB-039CT | Anti-Human HER2/neu Recombinant Antibody (h1E11) | WB | Humanized antibody |
TAB-041CT | Human Anti-ERBB2 Recombinant Antibody (TAB-041CT) | SPR, ELISA, WB | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-761 | Anti-ERBB2 Recombinant Antibody (Margetuximab) | IF, IP, Neut, FuncS, ELISA, FC, WB | IgG1 - kappa |
TAB-049CT | Anti-Human HER2/neu Recombinant Antibody (ChA21) | IHC, Inhib, WB, Activ, FC | Chimeric antibody (mouse/human) |
TAB-049CT-S(P) | Anti-Human HER2/neu Recombinant Antibody scFv Fragment (ChA21) | WB | Chimeric antibody (mouse/human) |
TAB-049CT-F(E) | Anti-Human HER2/neu Recombinant Antibody Fab Fragment (ChA21) | WB | Chimeric antibody (mouse/human) |
CAT | Product Name | Application | Type |
---|---|---|---|
AGTO-G022E | Anti-ERBB2 immunotoxin 4D5 (scFv)-PE | Cytotoxicity assay, Function study | |
AGTO-G022D | Anti-ERBB2 immunotoxin 4D5 (scFv)-DT | Cytotoxicity assay, Function study | |
AGTO-G022G | Anti-ERBB2 immunotoxin 4D5 (scFv)-Gel | Cytotoxicity assay, Function study | |
AGTO-G022R | Anti-ERBB2 immunotoxin 4D5 (scFv)-RTA | Cytotoxicity assay, Function study | |
AGTO-G022S | Anti-ERBB2 immunotoxin 4D5 (scFv)-Sap | Cytotoxicity assay, Function study |
CAT | Product Name | Application | Type |
---|---|---|---|
PSBW-161 | Mouse Anti-ERBB2 Recombinant Antibody (clone chA21); scFv Fragment | FC, WB | Mouse scFv |
PSBC-157 | Human Anti-ERBB2 Recombinant Antibody (clone F0178C1); scFv Fragment | Neut | Human scFv |
PSBC-158 | Human Anti-ERBB2 Recombinant Antibody (clone Pertuzumab, 2C4); scFv Fragment | IP, Neut | Human scFv |
FAMAB-0098-YC-F(E) | Mouse Anti-ERBB2 Recombinant Antibody (clone E402); Fab Fragment | Cyt | Mouse Fab |
FAMAB-0099-YC-F(E) | Human Anti-ERBB2 Recombinant Antibody (clone CH402); Fab Fragment | Cyt | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-034CT-F(E) | Anti-Human HER2/neu Recombinant Antibody Fab Fragment (pertuzumab ) | WB | |
TAB-036CT-F(E) | Anti-Human HER2/neu Recombinant Antibody Fab Fragment (6B2) | ELISA, WB | |
TAB-037CT-F(E) | Anti-Human HER2/neu Recombinant Antibody Fab Fragment (7C2/7F3) | ELISA, WB | |
TAB-270CQ | Mouse Anti-ERBB2 Recombinant Antibody (TAB-270CQ) | WB, Inhib | Mouse IgG |
PABX-082-S (P) | Recombinant Human Anti-HER2 Antibody scFv Fragment (Gr6) | WB, ELISA, FuncS | scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-042CT-F(E) | Anti-Human HER2/neu Recombinant Antibody Fab Fragment (CRX01) | WB | Human antibody |
TAB-043CT-F(E) | Human Anti-ERBB2 Recombinant Antibody; Fab Fragment (TAB-043CT-F(E)) | ELISA, Inhibion | Human Fab |
TAB-044CT-F(E) | Anti-Human HER2/neu Recombinant Antibody Fab Fragment (MIL5) | WB | Human antibody |
TAB-045CT-F(E) | Anti-Human HER2/neu Recombinant Antibody Fab Fragment (Erbicin) | ELISA, Inhibition | Human antibody |
TAB-048CT-F(E) | Human Anti-ERBB2 Recombinant Antibody; Fab Fragment (TAB-048CT-F(E)) | ELISA, WB | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-024LC | Recombinant Anti-Human ERBB2 Antibody (Fab glycosylation) | ELISA | Mouse antibody |
Gly-039LC | Recombinant Anti-Human ERBB2 Antibody (Fab glycosylation) | ELISA | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-117LC | Recombinant Anti-Human ERBB2 Antibody (Fc glycosylation) | ELISA | Humanized antibody |
Gly-118LC | Recombinant Anti-Human ERBB2 Antibody (Fc glycosylation) | ELISA | Mouse antibody |
Gly-145LC | Recombinant Anti-Human ERBB2 Antibody (Fc glycosylation) | ELISA | Human antibody |
Gly-146LC | Recombinant Anti-Human ERBB2 Antibody (Fc glycosylation) | ELISA | Human antibody |
Gly-147LC | Recombinant Anti-Human ERBB2 Antibody (Fc glycosylation) | ELISA | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-177LC | Recombinant Anti-Human ERBB2 Antibody (Non-glycosylated) | ELISA | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
BRD-0195MZ | Chicken Anti-ERBB2 Polyclonal IgY | WB | Chicken antibody |
BRD-0695MZ | Chicken Anti-ERBB2 Polyclonal IgY | WB | Chicken antibody |
BRD-0779MZ | Chicken Anti-ErbB2 Polyclonal IgY | ICC, IF, IHC, IP | Chicken antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-737CQ | Mouse Anti-ERBB2 Recombinant Antibody (clone 7.16.4) | Block, IP, IF, FC | Mouse IgG2a |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-1178 | Hi-Affi™ Rabbit Anti-ERBB2 Recombinant Antibody (clone DS1178AB) | IHC-P, IHC-Fr | Rabbit IgG |
MOR-4586 | Hi-Affi™ Rabbit Anti-ERBB2 Recombinant Antibody (clone TH99DS) | WB | Rabbit IgG |
MOR-4587 | Hi-Affi™ Rabbit Anti-ERBB2 Recombinant Antibody (clone TH100DS) | WB | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0021-YC | Human Anti-ERBB2 Recombinant Antibody (HPAB-0021-YC) | ELISA, Neut, FC, FuncS | Human IgG |
HPAB-0010-FY | Human Anti-ERBB2 Recombinant Antibody (HPAB-0010-FY) | ELISA, FC, ADCC | Human IgG1, κ |
HPAB-0011-FY | Mouse Anti-ERBB2 Recombinant Antibody (HPAB-0011-FY) | Inhib, ADCC, FuncS | Mouse IgG1, κ |
HPAB-0733LY | Human Anti-ERBB2 Recombinant Antibody (clone AH06) | ELISA | Human IgG |
HPAB-0734LY | Human Anti-ERBB2 Recombinant Antibody (clone A058) | ELISA | Human IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-468CQ | Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Timigutuzumab), ADCC Enhanced | ELISA, IHC, FC, IP, IF, FuncS | ADCC enhanced antibody |
AFC-TAB-053 | Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Pertuzumab), ADCC Enhanced | FuncS, IF, Neut, ELISA, FC, IP | ADCC enhanced antibody |
AFC-TAB-761 | Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Margetuximab), ADCC Enhanced | IF, IP, Neut, FuncS, ELISA, FC | ADCC enhanced antibody |
AFC-TAB-005 | Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Trastuzumab), ADCC Enhanced | FC, IP, ELISA, Neut, FuncS, IF | ADCC enhanced antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
MHC-CN0641 | PE-A*02:01/Human ERBB2 (LIAHNQVRQV) MHC Tetramer | FCM, IHC | |
MHC-CN0642 | APC-A*02:01/Human ERBB2 (LIAHNQVRQV) MHC Tetramer | FCM, IHC | |
MHC-CN0643 | FITC-A*02:01/Human ERBB2 (LIAHNQVRQV) MHC Tetramer | FCM, IHC | |
MHC-CN0644 | A*02:01/Human ERBB2 (LIAHNQVRQV) MHC Tetramer | FCM, IHC | |
MHC-CN0645 | PE-A*02:01/Human ERBB2 (ILHDGAYSL) MHC Tetramer | FCM, IHC |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0431-FY-S(P) | Human Anti-ERBB2 Recombinant Antibody; scFv Fragment (HPAB-0431-FY-S(P)) | ELISA, FC, WB | Humanized scFv |
HPAB-0432-FY-S(P) | Human Anti-ERBB2 Recombinant Antibody; scFv Fragment (HPAB-0432-FY-S(P)) | ELISA, FC, WB | Humanized scFv |
HPAB-1265WJ-S(P) | Human Anti-ERBB2 Recombinant Antibody; scFv Fragment (HPAB-1265WJ-S(P)) | ELISA | Humanized scFv |
FAMAB-0173JF-S(P) | Human Anti-ERBB2 Recombinant Antibody (clone C6H211); scFv Fragment | ELISA, FuncS | Human scFv |
PSBS-0070 | Human Anti-ERBB2 Recombinant Antibody; scFv Fragment (PSBS-0070) | ELISA, FuncS | Human scFv |
There are currently no Customer reviews or questions for TAB-050CT. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.